Ιατρικά Άρθρα: Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Τρίτη 13 Νοεμβρίου 2018

Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Conditions: Stage II-IVB Operable HNSCC Oral Cavity; Hypopharynx; Oropharynx; Larynx
Interventions: Drug: Durvalumab; Drug: durvalumab + tremelimumab
Sponsor: Yonsei University
Not yet recruiting

https://ift.tt/2qL8jn4

Ιατρικά Άρθρα

Ετικέτες

Τρίτη 13 Νοεμβρίου 2018

Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Multifunctional Two-Dimensional Bi<sub>2</sub>Se<sub>3</sub> Nanodiscs for Anti-Inflammatory Therapy of Inflammatory Bowel Diseases

Αναζήτηση αυτού του ιστολογίου

Αναφορά κατάχρησης